Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TEV-48125- 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TEV-48125 - 1 | EXPERIMENTAL | Dose Regimen 1 |
| TEV-48125 - 2 | EXPERIMENTAL | Dose Regimen 2 |
| TEV-48125 - 3 | EXPERIMENTAL | Dose Regimen 3 |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| Name | Type | Description |
|---|---|---|
| TEV-48125 - 1 | DRUG | Subcutaneous administration Dose Regimen 1 |
| TEV-48125 - 2 | DRUG | Subcutaneous administration Dose Regimen 2 |
| TEV-48125 - 3 | DRUG | Subcutaneous administration Dose Regimen 3 |
| Placebo | DRUG | Matching Placebo |
Inclusion Criteria: * The subject is a man or woman, 18 to 55 years of age, inclusive * The subject has a body mass index (BMI) ranging from 17.5 to 28.0 kg/m2, inclusive * The subjects must be in a good health at screening and check-in Additional inclusion criteria for Japanese subjects: * Subje...
TEV-48125 is an investigational small molecule being studied for pharmacokinetics. It is in Phase 1 clinical development, with a completed trial assessing its pharmacokinetics, safety, and tolerability in healthy subjects. It is not approved and remains in clinical development.
TEV-48125 is being developed by Teva Pharmaceutical Industries Limited, traded on the New York Stock Exchange under the ticker TEVA. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy volunteers.
TEV-48125 is in Phase 1 clinical development. One Phase 1 trial has been completed, which studied the drug's pharmacokinetics, safety, and tolerability. The drug is investigational and has not been approved.
TEV-48125 has one completed clinical trial, NCT02673567, which assessed pharmacokinetics, safety, and tolerability after a single subcutaneous administration in Japanese and Caucasian healthy subjects. The trial enrolled 64 participants in the United States.
TEV-48125 and TEV-48125-1 refer to the same drug candidate. The clinical trial NCT02673567 uses the name TEV-48125, and the drug is also identified as TEV-48125-1 in development records.